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Chordoma is a rare, slow-growing malignant tumor arising from notochordal remnants. A retrospective review of patient records
at two major referral centers was undertaken to assess the incidence, location, and prognostic factors of metastatic disease
from chordoma. 219 patients with chordoma (1962–2009) were identified. 39 patients (17.8%) developed metastatic disease, most
frequently to lung (>50%). Median survival from the time of initial diagnosis was 130.4 months for patients who developed
metastatic disease and 159.3 months for those who did not (𝑃 = 0.05). Metastatic disease was most common in the youngest
patients (𝑃 = 0.07), and it was 2.5 times more frequent among patients with local recurrence (26.3%) than in those without (10.8%)
(𝑃 = 0.003). Patient survival with metastatic disease was highly variable, and it was dependent on both the location of the tumor
primary and the site of metastasis. Metastasis to distal bone was the most rapid to develop and had the worst prognosis.
1. Introduction
Chordoma is a rare, slow-growing, malignant tumor arising
from notochordal remnants. Chordoma accounts for 1–4% of
primary bone tumors [1, 2] and has an estimated incidence
of 8/10,000,000/year [3]. Chordoma occurs primarily in the
fifth and sixth decades of life and more frequently affects
males (2 : 1), yet demographics can vary based on site of
presentation [2–4]. Due to a slow growth rate and nonspecific
presentation, diagnosis is delayed 1.5 years on average [5],
leading to more advanced disease by the time treatment
is initiated [2]. Despite its slow progression, patients with
chordoma have a poor prognosis, likely due to tumor location
and its propensity toward local recurrence (68%) [5–9],
resulting in diminished 5-year (67%) and 10-year (40%)
survival [3].
Since its description 150 years ago there has been relatively
sparse clinical data collected on chordoma. The few studies
describing metastatic disease in chordoma report an esti-
mated frequency of metastasis ranging from 3 to 48% [4] and
suggest that the presence of metastasis increases the risk of
tumor-related death [6]. Metastasis is relatively uncommon,
with lung representing the most common site. Metastases to
liver, bone, lymph nodes, skin, subcutaneous tissue, muscle,
peritoneum, heart, pleura, spleen, kidney, bladder, pancreas,
and brain have also been described [6, 9–11]. Factors that
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may be predictive of metastasis include local recurrence,
large tumor size, inadequate surgical margins, necrosis, long
clinical duration, and exposure to high dose radiation [4, 9,
11]. However, a recent study reported no significant difference
in likelihood of metastasis based on age, gender, tumor
location, or radiation therapy [9]. Earlier studies suggest a
relationship between primary tumor location and metastatic
disease risk [4, 12, 13], though the strength of this correlation
is uncertain as these reports contain conflicting data and
relatively few patients [6]. To better understand patterns of
metastatic disease from chordoma, we conducted a retro-
spective review of 219 patients with primary chordoma, 39 of
whom developed metastatic disease.
2. Methods
2.1. Patient Data Collection. A retrospective review of all
cases of chordoma diagnosed from November 1962 to Octo-
ber 2009 at two major US referral centers, Mass General
Hospital, Boston, MA, and University of Miami, Miami, FL,
was undertaken. Patient characteristics were recorded and
charts, radiographs, and histological slides were reviewed for
sites of primary and metastatic lesions. Bone scans, MRI,
chest radiographs, and/or CT scans were also reviewed. The
following data were obtained or defined: patient age, gender,
site of primary tumor, local recurrence, metastasis, site of
primary metastasis, presence of multiple metastasis, site of
secondary metastasis, and survival. Due to the rare incidence
of chordoma and lack of published large scale retrospective
studies, we focused only on the prognostic factors of the
disease and did not include the effects of treatment or cause
of patient death.
Frequencies and descriptive statistics were obtained for
analysis; categorical variables were examined using chi-
square and Fisher’s exact tests, where appropriate. Kaplan-
Meier survival curves with log rank analysis were performed
for survival, time from onset to metastasis, and time from
metastasis to death. Survival was defined as time from diag-
nosis to date of death. Patients surviving beyond the study
cutoff date were censored.There was sufficient data to analyse
219 patients, yet only 177 cases of primary chordoma could
be used for survival analysis (see Figure 1 and Table 2(a)).
Excluded from the analysis were individuals known to be
deceased, but for which no date of death could be defined,
and those lost to follow-up whose status (living or deceased)
was unknown. Excluded from analyses involving primary
tumor location were individuals with unknown, multiple, or
atypical sites of presentation (see Figure 2 and Table 5(a)).
Censored observations and data points are presented as
vertical hashmarks in the survival curves. This study was
approved by the institutional review boards of the respective
institutions: UM/JMH IRB 20100483 and MGH IRB 2003-P-
000987/5.
3. Results
3.1. Patient Population and Disease Presentation. 219 patients
with chordoma presented to the Orthopaedics Services at
two major referral centers in a 46-year span (Table 1). There
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Figure 1: Survival distribution stratified by presence of metastatic
disease. Diamonds represent censored data points.
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Figure 2: Survival distribution stratified by primary tumor location.
Diamonds represent censored data points.
were 137 (63%) men and 81 (37%) women. Age at diagnosis
was divided into quartiles, with most individuals in the third
quartile (median age at diagnosis 57, range: 3–88 years). The
most frequent site of presentation was sacral (60.7%). A few
primary tumors were documented in the clivus/skull base
(1.8%), and the remaining were observed in the mobile spine
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Table 1
Patient
characteristics 𝑛 (%)
Total number 219
Gender Male 137 (63)
Female 81 (37)
Age (years) Median 57
Range 3–88
Age quartiles
Q1: (3–24 yrs) 9 (4.1)
Q2: (25–46 yrs) 49 (22.4)
Q3: (47–68 yrs) 116 (53)
Q4: (69–88 yrs) 45 (20.5)
Presenting site
Clivus 4 (1.8)
Cervical spine 22 (10.0)
Lumbar spine 38 (17.4)
Thoracic spine 16 (7.3)
Sacrum 133 (60.7)
Multiple 4 (1.8)
Extension of
disease
Primary only 107 (47.4)
Recurrent (−) metastasis 73
Recurrent (+) metastasis 26
Total locally residual/recurrent
disease 99 (45.2)
Metastasis (+) local recurrence 26
Metastasis (−) local recurrence 13
Total metastatic 39 (17.8%)
(34.7%), which is further subdivided into lumbar (17.4%),
cervical (10.0%), and thoracic (7.3%).
Chordoma location at initial presentation trended toward
a dependence on patient age (𝑃 = 0.06). The youngest
patients (Q1: 3–24 yrs old) tended to have atypical primary
tumor locations, with chordoma appearing in the cervical
spine (50%, 𝑛 = 4) more frequently than the sacrum (37.5%,
𝑛 = 3) and clivus (12.5%, 𝑛 = 1). The remaining age quartiles
(Q2–Q4: >25 yrs old) were more likely to have involvement
in the typical/classical sacrococcygeal region (62.5–64.4%)
than in the lumbar (12.5–21.4%), cervical (6.7–14.6%), tho-
racic spine (7.1–8.9%), and clivus (0.9–2.2%). Patients with
youngest age of presentation (Q1) were more likely to be
female (56% F : 44% M) as compared to older quartiles Q2–
Q4wheremales predominated (Q2–Q4 = 27–38% F : 60–73%
M).Additionally, patientswith primary tumors of the cervical
spine were more likely to be female as well (54.4% F : 45.5%
M). Clival chordomas were found to occur equally among the
genders, with sacral, thoracic, and lumbar chordoma more
frequently occurring inmales (64.4–68.8%M : 31.3–35.6% F).
3.2. Overall Survival. Median overall survival was 140.5
months (95% CI 115.7–165.3) (Table 2(c)). The duration of
survival differed based on site of presentation; individuals
with primary tumors of the cervical and thoracic spine had
the shortest median survival at 74.7 and 76.8 months, respec-
tively. Those with primary tumors of the lumbar spine had
median survival of 126.7 months, while those with primary
tumors of the sacrumhad the longest median survival at 159.3
months.
While median survival did not differ based on presence
of local disease recurrence alone, median survival among
patients with metastatic disease (Table 2(a)) was significantly
(𝑃 = 0.05) (Table 2(b)) lower (130.4 months [95% CI 111.4–
149.5]) than patients withoutmetastatic disease (159.3months
[95% CI 123.9–194.6]) (Figure 1, Table 2(c)).
3.3. Metastasis. Of the 39 (17.8%) patients who devel-
oped metastatic disease, lung was most frequently involved
(53.8%). Other sites of primary metastasis include distal
bone (20.5%), soft tissue (15.4%), and liver (7.7%) (Table 3).
Metastatic disease was most frequent among the youngest
patients (Q1 44%, Q2 16%, Q3 20%, and Q4 9%) (𝑃 = 0.07)
and 2.5 times more frequent among patients with local recur-
rence (26.3%) than without (10.8%) (𝑃 = 0.003). Tumors
presenting in the cervical spine rarely became metastatic
(1 [4.5%] of 22), whereas tumors in the remainder of the
mobile spine demonstrated metastatic rates ranging from 17
to 32% (Table 4). Throughout the course of their illness, 99
patients (45.2%) developed locally recurrent disease (Table 1),
with lumbar chordoma being the most likely to recur. If
disease was first locally recurrent, these lesions took longer
to metastasize (67.2 months versus 20.5 months) (𝑃 ≤
0.001) and progressed more slowly from the diagnosis of
metastasis to death (22.1 months) than disease that was
directly metastatic (4.5 months).
The time from onset to metastasis was found to differ
significantly, depending on the site of presentation (𝑃 =
0.013). The shortest duration from onset to metastasis was
found among patients with primary tumors located in the
cervical spine (16.0 months). Time to metastasis of primary
tumors located in the thoracic spine, lumbar spine, and
sacrum was 22.0 months, 49.2 months, and 58.3 months,
respectively.The longest time to metastasis was 120.1 months,
which was observed in a patient with a primary clival
chordoma.
3.4. Survival among Patients withMetastatic Disease. Among
patients with metastasis (Table 5(a)), survival differed based
on primary tumor location (𝑃 = 0.05) (Table 5(b)). Patients
with metastatic tumors originating in the cervical spine had
the shortest median survival (20.4 months, 𝑛 = 1), followed
by tumors of the thoracic spine (70.1 months, 𝑛 = 3), lumbar
spine (104.9 months, 𝑛 = 4), and sacrum (130.4 months, 𝑛 =
16) (Figure 2, Table 5(c)).
Survival differed significantly based on site of metastasis
(𝑃 = 0.01) (Tables 6(a) and 6(b)). Tumors that first
metastasized to bone had the shortest median survival at
46 months, followed by liver at 72 months (Table 6(c)).
Sites of primary metastasis with the longest median survival
were lung and soft tissue, at 130 months and 132 months,
respectively (Figure 3, Table 6(c)).
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Table 2: Survival distribution stratified by presence of metastatic disease.
(a) Case processing summary of patients included in analysis
Metastasis Total𝑁 𝑁 of events Censored
𝑁 Percent
No 150 63 87 58.0%
Yes 27 22 5 18.5%
Overall 177 85 92 52.0%
(b) Overall statistical comparison and test of equality of survival distribu-
tions
Chi-Square df Sig.
Log rank (Mantel-Cox) 3.682 1 0.055
(c) Means and medians for survival time. Estimation is limited to the largest survival time if it is censored
Metastasis
Mean Median
95% Conf. interval 95% Conf. interval
Estimate Std. error Lower bound Upper bound Estimate Std. error Lower bound Upper bound
No 188.5 13.9 161.3 215.6 159.3 18.1 123.9 194.6
Yes 134.2 20.6 93.8 174.6 130.4 9.7 111.4 149.5
Overall 177.8 12.5 153.3 202.2 140.5 12.7 115.7 165.3
Table 3: Primary metastasis.
Primary metastatic site Total (𝑛) %
Lung 21 53.8%
Liver 3 7.7%
Bone 6 15.4%
Sternum 2 5.1%
Soft tissue 6 15.4%
Site not listed 1 2.6%
Total 39 17.8%
4. Discussion
4.1. Disease Presentation. In agreement with previous stud-
ies, individuals presenting with the typical sacrococcygeal
chordoma tended to be males in the 6th and 7th decades of
life, with a relatively good prognosis. Our data demonstrate,
also in agreement with previous studies, that patients over 25
years of age were more likely to be male and to present with
chordoma in the sacral, thoracic, or lumbar spine [12, 14].
The literature also describes a younger, atypical population
of chordoma patients with cranial primaries [3, 15], but our
data suggest that this atypical, young female predominant
group (under 25 yo.) has a predisposition toward aggressive
chordomas of the cervical spine. And although this atypical
group of patients represents less than 5% of the chordoma
population, cervical chordoma presentation has the lowest
survival of 74.7 months. Thus, in concordance with prior
study, our data reproduce two distinct groups: (1) an atypical
group of young female patients who predominantly present
with a more aggressive form of cervical chordoma, and (2)
a more common, typical group composed predominantly
of older male patients with sacral, thoracic, and lumbar
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Figure 3: Survival distribution among patients with metastasis
stratified by location of metastatic disease. Diamonds represent
censored data points.
tumors. It is unclear from our data whether the relatively
poor prognosis of the atypical female cervical chordomas is
secondary tomore aggressive inherent tumor properties or to
the anatomical constraints imposed on surgical intervention
in the cervical spine.
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Table 4: Patterns of primary metastasis.
Primary tumor site Total (𝑛) Metastatic (𝑛) % Site of primary metastasis
Clivus 4 1 25% Soft tissue [calf]
Cervical spine 22 1 4.5% Lung
Lumbar spine 38 7 18.4%
Sternum (2)
Lung (3)
Soft tissue [1: abdomen, 1: groin and psoas muscle]
Sacrum 133 23 17.3%
Lung (13)
Liver (3)
Bone [1: lumbar spine, 3: thoracic spine, 1: multiple bone sites] (5)
Soft tissue (2)
Thoracic spine 16 5 31.3%
Lung (3)
Bone [trochanter] (1)
Soft tissue [abdominal wall] (1)
Multiple primary sites 4 1 Lung
Posterior mediastinum 1 0
Not documented 1 1 Lung
Total 219 39 17.4%
Table 5: Survival distribution stratified by primary tumor location.
(a) Case processing summary of patients included in analysis
Primary tumor
location Total𝑁 𝑁 of events
Censored
𝑁 Percent
Cervical 1 1 0 0%
Lumbar 4 4 0 0%
Sacral 16 12 4 25%
Thoracic 3 3 0 0%
Overall 24 20 4 16.7%
(b) Overall statistical comparison and test of equality of survival distribu-
tions
Chi-Square df Sig.
Log rank (Mantel-Cox) 7.917 3 0.048
(c) Means and medians for survival time. Estimation is limited to the largest survival time if it is censored
Primary tumor
location
Mean Median
95% Conf. interval 95% Conf. interval
Estimate Std. error Lower bound Upper bound Estimate Std. error Lower bound Upper bound
Cervical 20.4 N/A 20.4 20.4 20.4 N/A N/A N/A
Lumbar 106 13.1 80.1 131.8 104.9 24.1 57.6 152.2
Sacral 127.9 20.7 87.4 168.4 130.4 3.8 123 137.9
Thoracic 82.6 31.8 20.4 144.9 70.1 28.7 13.9 126.3
Overall 111.7 14.6 83 140.5 128 18.4 92 164
4.2. Predicting Metastasis. In concordance with prior litera-
ture, nearly half of the individuals in the present study had
local recurrence during the course of their disease. As in
the literature, we found a significant correlation between the
presence of local recurrence and the subsequent development
of metastasis [4, 6, 9]. Interestingly, in contrast to this general
rule, while lumbar chordoma was often recurrent, there was
a relative lack of metastatic disease originating from this
site. The strong correlation between local recurrence and
subsequent metastasis reinforces the importance of local
tumor control, as our data suggest that chordomas may
acquire metastatic potential with uncontrolled growth at the
primary site.
4.3. Patterns of Metastatic Disease and Prognosis. There is
a paucity of data in the chordoma literature describing the
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Table 6: Survival distribution among patients with metastasis stratified by location of metastatic disease.
(a) Case processing summary of patients included in analysis
Location of
primary metastasis Total𝑁 𝑁 of events
Censored
𝑁 Percent
Bone 3 3 0 0%
Liver 2 1 1 50.0%
Lung 16 14 2 12.5%
Soft tissue 1 1 0 0%
Overall 22 19 3 13.6%
(b) Overall statistical comparison and test of equality of survival distribu-
tions
Chi-Square df Sig.
Log rank (Mantel-Cox) 11.260 3 0.010
(c) Means and medians for survival time. Estimation is limited to the largest survival time if it is censored
Location of
primary metastasis
Mean Median
95% Conf. interval 95% Conf. interval
Estimate Std. error Lower bound Upper bound Estimate Std. error Lower bound Upper bound
Bone 48 8.2 32 64 46 8.9 28.4 63.6
Liver 81 6 68.7 92.3 72 N/A N/A N/A
Lung 123.3 15.7 92.6 154.1 130 1.8 126.4 133.6
Soft tissue 133 0 133 133 132 N/A N/A N/A
Overall 111.6 13.1 86 137.4 128 16.8 97.1 163
expected time to metastasis. One study addressed this issue,
reporting times to metastasis ranging from 0.2 to 13.3 years
[6]. In our large cohort, we found themedian time from initial
diagnosis to metastasis to be 4.8 years (58.3mo), with most
individuals developing metastasis between 2.9 and 6.7 years.
After metastatic disease is diagnosed, our data show survival
to be highly variable, dependent on both the location of the
tumor primary and the site of metastasis, with amedian of 1.7
years between the diagnosis of metastatic disease and patient
death, similar to one study by Bergh et. al. [6]. Metastasis to
distal bone was the most rapid to develop and had the worst
prognosis.
Although initially contested, recent literature identifies
lung to be the most common site for chordoma metastasis
[9]. In our data, lungmetastases account formore than 50%of
all metastatic disease, making lung metastases approximately
three times more common than bone and soft tissue, which
are the second and third most frequent sites of metastatic
disease. And interestingly, metastatic disease to bone and soft
tissue almost always arises from locally recurrent chordoma.
In contrast, metastasis to the lung was associated with prior
local recurrence in only half of the cases.
5. Conclusion
Our large retrospective study pooled data from two major
cancer centers to characterize the incidence, location, and
prognostic factors of metastatic disease in patients with
primary chordoma. Lung is the favored site for metastasis
(>50%). Metastatic disease most commonly occurred in the
youngest patients (<25 years old) (𝑃 = 0.07), and it was 2.5
times more frequent among patients with local recurrence
(26.3%) than in those without (10.8%) (𝑃 = 0.003). Patient
survival with metastatic disease was highly variable, and it
was dependent on both the location of the tumor primary
chordoma and the site of metastasis. But overall, metastatic
disease is a poor prognosticator. The median survival from
the time of initial diagnosis is 130.4 months for patients who
developed metastatic disease and 159.3 months for those who
did not (𝑃 = 0.05). Metastasis to distal bone was the most
rapid to develop and had the worst prognosis.
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